Merck & Co. Inc. (MRK) announced the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMEA has recommended approval of ELONVA, or corifollitropin alfa injection, as a treatment in controlled ovarian stimulation or COS in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology or ART program. If approved by the European Commission, Merck would receive marketing authorization for ELONVA with unified labeling valid in all European Union Member States.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.